Right first time: Pioneering new methods of drug manufacture

13-Nov-2009 - Engineers at the University of Leeds have developed a simple technology which can be used in existing chemical reactors to ensure "right first time" drug crystal formation. Ensuring drug crystals are formed correctly is crucial to their efficacy and the efficiency of pharmaceutical manufacturers' ...

PLIVA to File Lawsuit Against HANFA

26-Jan-2007 - PLIVA d.d. announced that it plans to file a lawsuit against the Croatian Financial Services Supervisory Agency (HANFA) with the Administrative Court of the Republic of Croatia, following the notification received on 22 January 2007 of HANFA's Ruling that PLIVA withheld price-sensitive ...

PLIVA Announces Changes in Management and Supervisory Boards

PLIVA's Supervisory Board Appoints Three New Members to Management Board

02-Nov-2006 - Barr Pharmaceuticals, Inc. and its newly acquired subsidiary PLIVA d.d. announced changes to the Management and Supervisory Boards of PLIVA d.d. The changes resulted from the meeting of PLIVA's Supervisory Board that was held on October 30, 2006 in Zagreb, Croatia. Following the successful ...

Actavis divests its stake in PLIVA

24-Oct-2006 - Actavis Group announced that a total of 20.8% of PLIVA's share capital that Actavis controls through a combination of share ownership and options to acquire shares has been tendered into Barr's offer to acquire all outstanding shares in PLIVA at HRK820 per share. The shareholding was a strategic ...

Barr Acquires PLIVA d.d. Following Official Closing of Tender Offer Process

23-Oct-2006 - Barr Pharmaceuticals, Inc. and PLIVA d.d. announced that the Central Depository Agency ("CDA") has issued the final results of the tender process and that 17,056,977 shares, representing 92% of PLIVA's share capital, have been tendered to Barr's European subsidiary. Under the terms of Barr's ...

Actavis responds to Barr Pharmaceuticals' increased offer for PLIVA

20-Sep-2006 - Actavis Group has noted the increased offer published on September 11th, to acquire PLIVA, announced by Barr Pharmaceuticals. The Board of Actavis believes that its current offer of HRK 795 per share represents a full and fair price for PLIVA's shares including synergies expected to be realized ...

PLIVA Signs Agreement with Unichem for New Products in US

23-May-2006 - PLIVA d.d. announced that its US subsidiary has entered into a Product Development, Manufacturing and Supply Agreement with Unichem Laboratories Limited of India. The agreement involves five products, which are in an advanced stage of development, and allows for the inclusion of additional ...

PLIVA Completes Divestment of Research Institute

09-May-2006 - PLIVA d.d. announced that it has completed the divestment of PLIVA - Istrazivaki Institut d.o.o. (PLIVA - Research Institute Ltd.), PLIVA's proprietary R&D arm to GlaxoSmithKline (GSK). PLIVA received a payment of USD 35m upon closing of the transaction and is entitled to contingent payments ...

PLIVA Completes Divestment of Its Manufacturing Plant in Germany

08-May-2006 - PLIVA d.d. announced that its German subsidiary AWD.pharma GmbH & Co. KG has completed the divestment of its manufacturing plant in Dresden, Germany. The closing of the transaction will not have a material impact on PLIVA Group results for 2006 given that associated restructuring charges were ...

PLIVA to seek clarification of Actavis offer

24-Apr-2006 - PLIVA d.d. confirmed that it has received an increased preliminary proposal from Actavis for a potential cash consideration of HRK 630 per share, subject to a number of conditions, including the completion of satisfactory due diligence and funding. PLIVA notes Actavis' decision to increase the ...